MX2022010372A - Vacuna contra la infeccion por el virus de la peste porcina africana. - Google Patents

Vacuna contra la infeccion por el virus de la peste porcina africana.

Info

Publication number
MX2022010372A
MX2022010372A MX2022010372A MX2022010372A MX2022010372A MX 2022010372 A MX2022010372 A MX 2022010372A MX 2022010372 A MX2022010372 A MX 2022010372A MX 2022010372 A MX2022010372 A MX 2022010372A MX 2022010372 A MX2022010372 A MX 2022010372A
Authority
MX
Mexico
Prior art keywords
swine fever
african swine
fever virus
virus infection
vaccine against
Prior art date
Application number
MX2022010372A
Other languages
English (en)
Inventor
Simon Davis
Linda Dixon
Ana Reis
Yuan Jenq Lui
Shinji Ikemizu
Anusyah Rathakrishnan
Original Assignee
The Pirbright Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2003289.2A external-priority patent/GB202003289D0/en
Priority claimed from GBGB2003292.6A external-priority patent/GB202003292D0/en
Priority claimed from GBGB2005878.0A external-priority patent/GB202005878D0/en
Priority claimed from GBGB2005880.6A external-priority patent/GB202005880D0/en
Priority claimed from GBGB2013541.4A external-priority patent/GB202013541D0/en
Application filed by The Pirbright Inst filed Critical The Pirbright Inst
Publication of MX2022010372A publication Critical patent/MX2022010372A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/12011—Asfarviridae
    • C12N2710/12021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/12011—Asfarviridae
    • C12N2710/12034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/12011—Asfarviridae
    • C12N2710/12061—Methods of inactivation or attenuation
    • C12N2710/12062—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/12011—Asfarviridae
    • C12N2710/12071—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a virus de la ASF atenuados. Los virus atenuados protegen a los cerdos contra la exposición posterior a virus virulentos. La presente invención también se refiere al uso de esos virus atenuados para tratar y/o prevenir la peste porcina africana. La invención también se refiere a proteínas EP402R del virus de la ASF que comprenden sustituciones de aminoácidos particulares, así como a polinucleótidos que codifican para tales proteínas y a virus de la ASF que comprenden tales proteínas.
MX2022010372A 2020-03-06 2021-03-05 Vacuna contra la infeccion por el virus de la peste porcina africana. MX2022010372A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GBGB2003289.2A GB202003289D0 (en) 2020-03-06 2020-03-06 Vaccine
GBGB2003292.6A GB202003292D0 (en) 2020-03-06 2020-03-06 Vaccine
GBGB2005878.0A GB202005878D0 (en) 2020-04-22 2020-04-22 Vaccine
GBGB2005880.6A GB202005880D0 (en) 2020-04-22 2020-04-22 Vaccine
GBGB2013541.4A GB202013541D0 (en) 2020-08-28 2020-08-28 Vaccine
PCT/GB2021/050562 WO2021176236A1 (en) 2020-03-06 2021-03-05 Vaccine against african swine fever virus infection

Publications (1)

Publication Number Publication Date
MX2022010372A true MX2022010372A (es) 2023-01-19

Family

ID=74870840

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2022010373A MX2022010373A (es) 2020-03-06 2021-03-05 Vacuna contra el virus de la peste porcina africana.
MX2022010372A MX2022010372A (es) 2020-03-06 2021-03-05 Vacuna contra la infeccion por el virus de la peste porcina africana.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2022010373A MX2022010373A (es) 2020-03-06 2021-03-05 Vacuna contra el virus de la peste porcina africana.

Country Status (12)

Country Link
US (2) US20230117978A1 (es)
EP (3) EP4114453A1 (es)
JP (2) JP2023516713A (es)
KR (2) KR20230013017A (es)
CN (3) CN115605223A (es)
AU (2) AU2021231402A1 (es)
BR (2) BR112022016891A2 (es)
CA (2) CA3170058A1 (es)
CL (2) CL2022002416A1 (es)
CO (2) CO2022014152A2 (es)
MX (2) MX2022010373A (es)
WO (3) WO2021176236A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024031045A2 (en) * 2022-08-04 2024-02-08 Malcolm Thomas Dominant negative antigen approach for prophylactic and post-infection treatment of swine against african swine fever virus
WO2024057048A1 (en) * 2022-09-12 2024-03-21 Consejo Superior De Investigaciones Científicas Attenuated african swine fever virus and use thereof in vaccine compositions
WO2024110451A1 (en) * 2022-11-22 2024-05-30 Intervet International B.V. Attenuated african swine fever virus and use thereof in vaccine compositions
WO2024110453A1 (en) * 2022-11-22 2024-05-30 Gold Standard Diagnostics Madrid, S.A. Method for differentiating asfv infected from asfv vaccinated animals
CN117224669A (zh) * 2023-07-31 2023-12-15 中国农业科学院兰州兽医研究所 非洲猪瘟病毒mgf360-21r蛋白作为免疫诱导剂或者佐剂的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201410971D0 (en) * 2014-06-19 2014-08-06 Pirbright Inst The Vaccine
US9528094B2 (en) * 2014-11-10 2016-12-27 The United States Of America, As Represented By The Secretary Of Agriculture Attenuated African swine fever virus vaccine based in the deletion of MGF genes
CN110551695A (zh) * 2019-08-14 2019-12-10 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) 非洲猪瘟病毒四基因缺失弱毒株及其应用

Also Published As

Publication number Publication date
EP4114455A1 (en) 2023-01-11
CO2022014152A2 (es) 2023-02-16
CL2022002412A1 (es) 2023-03-03
MX2022010373A (es) 2023-01-19
JP2023516713A (ja) 2023-04-20
WO2021176235A1 (en) 2021-09-10
CN115605223A (zh) 2023-01-13
US20230124042A1 (en) 2023-04-20
WO2021176234A1 (en) 2021-09-10
JP2023516709A (ja) 2023-04-20
CL2022002416A1 (es) 2023-03-03
AU2021229654A1 (en) 2022-11-03
CN116133680A (zh) 2023-05-16
BR112022016893A2 (pt) 2023-01-24
AU2021231402A1 (en) 2022-11-03
EP4114453A1 (en) 2023-01-11
BR112022016893A8 (pt) 2023-02-28
EP4114454A1 (en) 2023-01-11
KR20230013016A (ko) 2023-01-26
WO2021176236A1 (en) 2021-09-10
US20230117978A1 (en) 2023-04-20
CA3170043A1 (en) 2021-09-10
KR20230013017A (ko) 2023-01-26
BR112022016891A2 (pt) 2023-01-24
CA3170058A1 (en) 2021-09-10
CO2022014256A2 (es) 2022-12-30
CN115397463A (zh) 2022-11-25

Similar Documents

Publication Publication Date Title
MX2022010372A (es) Vacuna contra la infeccion por el virus de la peste porcina africana.
MX2023000411A (es) Vacuna combinada de sars-cov-2 e influenza.
MX2021011687A (es) Composiciones inmunogenicas y vacunas que comprenden peptidos y proteinas del virus de la peste porcina africana y usos de las mismas.
EA202193251A1 (ru) Пептидомиметики для лечения коронавирусной и пикорнавирусной инфекций
MX2018014573A (es) Vacuna contra el virus del zika.
EP4104854A3 (en) Multivalent vaccines for rabies virus and coronaviruses
BR112018009032A8 (pt) vetor viral de arenavírus infeccioso, composição farmacêutica, composição imunogênica, vacina, método para o tratamento ou a prevenção de infecção pelo vírus da hepatite b em um paciente, uso de um vetor viral, ácido nucleico isolado, vetor viral de arenavírus infeccioso deficiente em replicação e método para sua geração
WO2017214596A8 (en) Compositions and methods for preventing and treating zika virus infection
EA029939B8 (ru) Человеческие связывающие молекулы, обладающие способностью нейтрализовывать вирус гриппа h3n2, и их применение
MX2017013956A (es) Analogos de nucleosidos para el tratamiento de la familia de virus flaviviridae y cancer.
PH12021550479A1 (en) Dengue vaccine unit dose and administration thereof
MX2022010588A (es) Vacuna basada en poxvirus recombinantes contra el virus sars-cov-2.
MX2019003682A (es) Antigenos de consenso del virus sincitial respiratorio humano, constructos de acido nucleico y vacunas hechas de estos, y metodos para utilizarlas.
MX2018010958A (es) Vacuna para virus de zika atenuado vivo.
BR112012021650A2 (pt) "parvovírus recombinante atenuado, vacina para a proteção de animais contra infecção com parvovírus, método para a obtenção de um parvovírus recombinante, e, uso de uma vacina."
MX2018015506A (es) Vacuna contra virus de bronquitis infecciosa.
PH12015501378B1 (en) Porcine parvovirus 5a, methods of use and vaccine
PH12015501721A1 (en) Porcine parvovirus 5b, methods of use and vaccine
PH12018501750A1 (en) Porcine reproductive and respiratory syndrome vaccine virus
MX2023012368A (es) Vacuna de virus.
PH12020551944A1 (en) Reverse peptide vaccine
EA202191147A1 (ru) Вакцина виб h52 с гетерологичным шиповидным белком
EA202091563A1 (ru) Человеческие антитела к гемагглютинину вируса гриппа
MX2021015938A (es) Virus para vacuna contra el síndrome respiratorio y reproductivo porcino.
PH12021550987A1 (en) Anti-rabies monoclonal antibodies and cocktail thereof